Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Haemodialysis patients suffer from accelerated vascular calcification.

The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification.

Who Took Part

According to the abstract, 200 patients were involved.

The age groups tagged for this paper are young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Dietary intake of vitamin K1 (phylloquinone) and menaquinone was estimated based on a detailed questionnaire.

How the Study Was Run

The design is described as randomized and single-blind.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.

A time span of 8 weeks appears in the methods.

Dp-uc-MGP was measured at baseline and after 8 weeks.

What Was Measured

Topics PubMed links to this paper include Calcium-Binding Proteins, Dietary Supplements, Extracellular Matrix Proteins, Hemostatics, Prognosis, Renal Dialysis and Surveys and Questionnaires.

Author keywords: haemodialysis, menaquinone and vascular calcification.

What This Means in Plain Language

The paper is a randomized and single-blind study of Vitamin D, K2, Magnesium and Zinc in 200 patients over 8 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.